2.19

5.80% 0.12

After Hours: 2.18 -0.010 -0.46%

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is traded at $2.19, with a volume of 1.39M. It is up +5.80% in the last 24 hours and up +42.21% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Previous Close:

$2.07

Open:

$2.06

24h Volume:

1.39M

Relative Volume:

1.02

Market Cap:

$294.69M

Revenue:

Net Income/Loss:

$-101.70M

P/E Ratio:

-1.155

EPS:

-1.8961

Net Cash Flow:

$-84.35M

1W Performance:

-0.45%

1M Performance:

+42.21%

6M Performance:

+102.78%

1Y Performance:

+375.98%

1-Day Range:

$2.026

$2.27

1-Week Range:

$1.975

$2.27

52-Week Range:

$0.4399

$2.66

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

650-466-7125

Address

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ALXO's Discussions on Twitter

Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALXO Alx Oncology Holdings Inc	2.19	278.55M	0	-101.70M	-84.35M	-1.8961
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-19-26	Initiated	Wells Fargo	Overweight
Mar-06-26	Resumed	UBS	Buy
Nov-13-25	Initiated	Jefferies	Buy
Mar-06-25	Upgrade	Jefferies	Hold → Buy
Dec-19-24	Downgrade	Jefferies	Buy → Hold
Mar-08-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

Jun 30, 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times

Jun 30, 2026

Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan

Jun 30, 2026

ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK

Jun 30, 2026

ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India

Jun 30, 2026

ALXO Welcomes New Leadership with Board Changes - GuruFocus

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network

Jun 30, 2026

ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union

Jun 30, 2026

Jun 29, 2026

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026